GLA and Fabry disease: Although there are clinically approved enzyme replacement therapies (ERTs), they fail to meet medical needs due to their inability to penetrate the blood-brain barrier.352 To this end, in 2019, DeRosa et al.351 and Zhu et al.353, respectively, reported systemically delivery of mRNA-encoding human alpha-galactosidase A (H-α-gal A) using LNPs, both of which indicated that mRNA LNPs was a potential treatment modality for FD.